Published in Am J Pathol on September 01, 2003
Ovarian cancer. Annu Rev Pathol (2009) 4.92
GARP (LRRC32) is essential for the surface expression of latent TGF-beta on platelets and activated FOXP3+ regulatory T cells. Proc Natl Acad Sci U S A (2009) 2.51
Pak protein kinases and their role in cancer. Cancer Metastasis Rev (2009) 2.44
Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas. Cancer Res (2009) 2.25
PAK signalling during the development and progression of cancer. Nat Rev Cancer (2014) 2.21
Pathways to tamoxifen resistance. Cancer Lett (2007) 2.12
Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells. Proc Natl Acad Sci U S A (2011) 2.01
Merlin/NF-2 mediates contact inhibition of growth by suppressing recruitment of Rac to the plasma membrane. J Cell Biol (2005) 1.86
PAK1 is a breast cancer oncogene that coordinately activates MAPK and MET signaling. Oncogene (2011) 1.54
PAK1 as a therapeutic target. Expert Opin Ther Targets (2010) 1.48
p21-Activated kinase 1 coordinates aberrant cell survival and pericellular proteolysis in a three-dimensional culture model for premalignant progression of human breast cancer. Neoplasia (2008) 1.48
p21-activated kinase 1: PAK'ed with potential. Oncotarget (2011) 1.44
Lessons from border cell migration in the Drosophila ovary: A role for myosin VI in dissemination of human ovarian cancer. Proc Natl Acad Sci U S A (2004) 1.34
PAK signaling in cancer. Cell Logist (2012) 1.27
Integrated analysis of breast cancer cell lines reveals unique signaling pathways. Genome Biol (2009) 1.25
Functional analysis of 11q13.5 amplicon identifies Rsf-1 (HBXAP) as a gene involved in paclitaxel resistance in ovarian cancer. Cancer Res (2009) 1.20
Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges. J Oncol (2009) 1.12
Amplification of the ch19p13.2 NACC1 locus in ovarian high-grade serous carcinoma. Mod Pathol (2011) 1.05
p21-activated kinases in Erbb2-positive breast cancer: A new therapeutic target? Small GTPases (2010) 1.00
Senescence-inducing stress promotes proteolysis of phosphoglycerate mutase via ubiquitin ligase Mdm2. J Cell Biol (2014) 0.95
Pak and Rac GTPases promote oncogenic KIT-induced neoplasms. J Clin Invest (2013) 0.94
PAK1 kinase promotes cell motility and invasiveness through CRK-II serine phosphorylation in non-small cell lung cancer cells. PLoS One (2012) 0.94
Ovarian cancer: linking genomics to new target discovery and molecular markers--the way ahead. Adv Exp Med Biol (2008) 0.92
ERK activation of p21 activated kinase-1 (Pak1) is critical for medulloblastoma cell migration. Clin Exp Metastasis (2010) 0.91
Genome profiling of ovarian adenocarcinomas using pangenomic BACs microarray comparative genomic hybridization. Mol Cytogenet (2008) 0.89
p21-Activated kinase-1 promotes aggressive phenotype, cell proliferation, and invasion in gestational trophoblastic disease. Am J Pathol (2010) 0.88
Reduced expression of p21-activated protein kinase 1 correlates with poor histological differentiation in pancreatic cancer. BMC Cancer (2014) 0.85
The interaction between C35 and ΔNp73 promotes chemo-resistance in ovarian cancer cells. Br J Cancer (2013) 0.85
P21-activated kinase 5 plays essential roles in the proliferation and tumorigenicity of human hepatocellular carcinoma. Acta Pharmacol Sin (2013) 0.84
Pak1/LIMK1/Cofilin Pathway Contributes to Tumor Migration and Invasion in Human Non-Small Cell Lung Carcinomas and Cell Lines. Korean J Physiol Pharmacol (2012) 0.84
Tyrosyl phosphorylated serine-threonine kinase PAK1 is a novel regulator of prolactin-dependent breast cancer cell motility and invasion. Adv Exp Med Biol (2015) 0.83
An approach to the validation of novel molecular markers of breast cancer via TMA-based FISH scanning. J Mol Histol (2007) 0.83
p21-activated kinase signaling in breast cancer. Breast Cancer Res (2004) 0.83
CDX-2 immunostaining in primary and secondary ovarian carcinomas. J Clin Pathol (2004) 0.81
The role of p21-activated kinases in hepatocellular carcinoma metastasis. J Mol Signal (2014) 0.81
PAK1 is a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome. Blood (2015) 0.80
Stromal expression of β-arrestin-1 predicts clinical outcome and tamoxifen response in breast cancer. J Mol Diagn (2011) 0.80
[Immunohistochemical characterization of salivary gland tumors with tissue micro-arrays]. Pathologe (2005) 0.80
Alpha-methylacyl-CoA racemase (AMACR) expression in epithelial ovarian cancer. Virchows Arch (2011) 0.79
[Molecular pathology of epithelial ovarian neoplasias: from the phenotype-genotype correlation to new targets in diagnostics and therapy]. Pathologe (2007) 0.77
From array to array: confirmation of genomic gains and losses discovered by array-based comparative genomic hybridization utilizing fluorescence in situ hybridization on tissue microarrays. J Mol Histol (2006) 0.75
Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med (1998) 25.41
High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet (1998) 21.52
AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science (1997) 8.05
Detection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridization. Proc Natl Acad Sci U S A (1994) 5.74
Cancer statistics, 1994. CA Cancer J Clin (1994) 4.14
Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Nat Genet (2000) 4.13
Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. J Natl Cancer Inst (2001) 2.93
Tissue microarrays for gene amplification surveys in many different tumor types. Clin Cancer Res (1999) 2.79
Regulatable expression of p21-activated kinase-1 promotes anchorage-independent growth and abnormal organization of mitotic spindles in human epithelial breast cancer cells. J Biol Chem (2000) 2.51
Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer. Clin Cancer Res (2000) 2.43
Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst (1992) 1.94
Genetic analysis of early- versus late-stage ovarian tumors. Cancer Res (2001) 1.77
P21-activated kinase-1 phosphorylates and transactivates estrogen receptor-alpha and promotes hyperplasia in mammary epithelium. EMBO J (2002) 1.75
Detection of multiple gene amplifications in glioblastoma multiforme using array-based comparative genomic hybridization. Lab Invest (2001) 1.50
Detailed map of a region commonly amplified at 11q13-->q14 in human breast carcinoma. Cytogenet Cell Genet (1997) 1.48
Cyclin gene amplification and overexpression in breast and ovarian cancers: evidence for the selection of cyclin D1 in breast and cyclin E in ovarian tumors. Int J Cancer (1996) 1.29
Chromosomal imbalances in papillary renal cell carcinoma: genetic differences between histological subtypes. Am J Pathol (1998) 1.24
Vascular endothelial growth factor up-regulation via p21-activated kinase-1 signaling regulates heregulin-beta1-mediated angiogenesis. J Biol Chem (2000) 1.18
The p16-cyclin D1/CDK4-pRb pathway and clinical outcome in epithelial ovarian cancer. Clin Cancer Res (1999) 1.11
Online access to CGH data of DNA sequence copy number changes. Am J Pathol (2000) 1.01
c-myc and chromosome 8 centromere studies of ovarian cancer by interphase FISH. Exp Mol Pathol (1999) 0.97
FISH characterization of head and neck carcinomas reveals that amplification of band 11q13 is associated with deletion of distal 11q. Genes Chromosomes Cancer (1998) 0.95
Trisomy 12 and K-ras-2 amplification in human ovarian tumors. Int J Cancer (1991) 0.94
Expression and subcellular localization of cyclin D1 protein in epithelial ovarian tumour cells. Br J Cancer (1999) 0.91
Chromosome 11q22.3-q25 LOH in ovarian cancer: association with a more aggressive disease course and involved subregions. Gynecol Oncol (1998) 0.91
Detection of c-erbB-2 and FGF-3 (INT-2) gene amplification in epithelial ovarian cancer. Int J Oncol (2000) 0.89
11q23.1 and 11q25-qter YACs suppress tumour growth in vivo. Oncogene (1999) 0.86
DNA ploidy and MYC DNA amplification in ovarian carcinomas. Correlation with p53 and bcl-2 expression, proliferative activity and prognosis. Virchows Arch (1996) 0.86
Allelic deletion at 11q23.3-q25 is an early event in cervical neoplasia. Oncogene (1998) 0.84
Amplification of C-MYC as the origin of the homogeneous staining region in ovarian carcinoma detected by micro-FISH. Cancer Genet Cytogenet (1999) 0.80
Amplifications of proto-oncogenes in ovarian carcinoma. Chin Med J (Engl) (1995) 0.79
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet (2012) 9.93
Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med (2010) 6.39
Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature (2003) 5.57
Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med (2002) 5.34
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet (2012) 5.28
EML4-ALK fusion lung cancer: a rare acquired event. Neoplasia (2008) 5.22
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov (2011) 4.80
Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant (2003) 4.54
Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res (2002) 4.36
Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors and its value as a serum marker in hepatocellular carcinomas. Hepatology (2009) 4.03
The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. Am J Surg Pathol (2013) 3.68
Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation (2005) 3.57
Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res (2009) 3.17
FAN1 mutations cause karyomegalic interstitial nephritis, linking chronic kidney failure to defective DNA damage repair. Nat Genet (2012) 2.74
p16INK4a immunohistochemistry improves interobserver agreement in the diagnosis of cervical intraepithelial neoplasia. Am J Surg Pathol (2002) 2.73
Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res (2004) 2.55
Osmotic nephrosis: acute kidney injury with accumulation of proximal tubular lysosomes due to administration of exogenous solutes. Am J Kidney Dis (2008) 2.24
Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum. Am J Surg Pathol (2007) 2.20
Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth. Cancer Res (2011) 2.08
Reliable detection of subclonal single-nucleotide variants in tumour cell populations. Nat Commun (2012) 2.06
Prognostic significance of epithelial-mesenchymal and mesenchymal-epithelial transition protein expression in non-small cell lung cancer. Clin Cancer Res (2008) 2.06
The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol (2013) 2.05
Establishment of a multicolour fluorescence in situ hybridisation-based assay for subtyping of renal cell tumours. Eur Urol (2013) 2.00
pVHL and GSK3beta are components of a primary cilium-maintenance signalling network. Nat Cell Biol (2007) 1.97
Fluorescence in situ hybridization (FISH) as an ancillary diagnostic tool in the diagnosis of melanoma. Am J Surg Pathol (2009) 1.87
Influence of slide aging on results of translational research studies using immunohistochemistry. Mod Pathol (2004) 1.75
pVHL and PTEN tumour suppressor proteins cooperatively suppress kidney cyst formation. EMBO J (2008) 1.72
Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer. Gynecol Oncol (2006) 1.69
Axillary lymph node dissection for sentinel lymph node micrometastases may be safely omitted in early-stage breast cancer patients: long-term outcomes of a prospective study. Ann Surg Oncol (2009) 1.67
SOX2 gene amplification and protein overexpression are associated with better outcome in squamous cell lung cancer. Mod Pathol (2011) 1.66
Autoantibodies against beta-amyloid are common in Alzheimer's disease and help control plaque burden. Ann Neurol (2009) 1.65
VHL loss causes spindle misorientation and chromosome instability. Nat Cell Biol (2009) 1.65
Consistent expression of the stem cell renewal factor BMI-1 in primary and metastatic melanoma. Int J Cancer (2007) 1.62
C3 deposition glomerulopathy due to a functional factor H defect. Kidney Int (2008) 1.61
Chromophobe renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 145 cases. Am J Surg Pathol (2008) 1.60
Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer. Proc Natl Acad Sci U S A (2011) 1.59
Diagnostic and prognostic molecular markers for renal cell carcinoma: a critical appraisal of the current state of research and clinical applicability. Eur Urol (2009) 1.58
Spectrum of epithelial neoplasms in end-stage renal disease: an experience from 66 tumor-bearing kidneys with emphasis on histologic patterns distinct from those in sporadic adult renal neoplasia. Am J Surg Pathol (2006) 1.58
A novel tumor grading scheme for chromophobe renal cell carcinoma: prognostic utility and comparison with Fuhrman nuclear grade. Am J Surg Pathol (2010) 1.55
In vivo electrophysiological effects of a selective slow delayed-rectifier potassium channel blocker in anesthetized dogs: potential insights into class III actions. Cardiovasc Res (2004) 1.55
Endothelial CCR2 signaling induced by colon carcinoma cells enables extravasation via the JAK2-Stat5 and p38MAPK pathway. Cancer Cell (2012) 1.55
Morphologic and molecular characterization of renal cell carcinoma in children and young adults. Am J Surg Pathol (2004) 1.53
Periostin expression and epithelial-mesenchymal transition in cancer: a review and an update. Virchows Arch (2011) 1.49
Sox10 promotes the formation and maintenance of giant congenital naevi and melanoma. Nat Cell Biol (2012) 1.48
VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma. J Pathol (2002) 1.48
A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma. Sci Transl Med (2011) 1.48
Patient blood management: the pragmatic solution for the problems with blood transfusions. Anesthesiology (2008) 1.46
Nanoparticle cytotoxicity depends on intracellular solubility: comparison of stabilized copper metal and degradable copper oxide nanoparticles. Toxicol Lett (2010) 1.45
Virtual slides: high-quality demand, physical limitations, and affordability. Hum Pathol (2003) 1.42
C4d staining of renal allograft biopsies: a comparative analysis of different staining techniques. Nephrol Dial Transplant (2006) 1.40
E2F3 amplification and overexpression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer. Oncogene (2004) 1.40
SOX2 amplification is a common event in squamous cell carcinomas of different organ sites. Hum Pathol (2011) 1.40
Intratumoral plasmacytoid dendritic cells associate with increased survival in patients with follicular lymphoma. Leuk Lymphoma (2011) 1.39
Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 Dual-stained cytology. Gynecol Oncol (2011) 1.38
Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study. J Natl Cancer Inst (2013) 1.38
KPNA2 expression is an independent adverse predictor of biochemical recurrence after radical prostatectomy. Clin Cancer Res (2011) 1.38
Histone deacetylase/acetylase activity in total synovial tissue derived from rheumatoid arthritis and osteoarthritis patients. Arthritis Rheum (2007) 1.38
Quantifying cancer progression with conjunctive Bayesian networks. Bioinformatics (2009) 1.37
Decentral gene expression analysis for ER+/Her2- breast cancer: results of a proficiency testing program for the EndoPredict assay. Virchows Arch (2012) 1.37
Lack of the transcriptional coactivator OBF-1 prevents the development of systemic lupus erythematosus-like phenotypes in Aiolos mutant mice. J Immunol (2003) 1.36
Computational pathology analysis of tissue microarrays predicts survival of renal clear cell carcinoma patients. Med Image Comput Comput Assist Interv (2008) 1.35
Tumor-associated macrophages subvert T-cell function and correlate with reduced survival in clear cell renal cell carcinoma. Oncoimmunology (2013) 1.35
[Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma. Clin Cancer Res (2007) 1.35
Conjunctive p16INK4a testing significantly increases accuracy in diagnosing high-grade cervical intraepithelial neoplasia. Am J Clin Pathol (2010) 1.34
EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations. Virchows Arch (2012) 1.34
HER3 is a determinant for poor prognosis in melanoma. Clin Cancer Res (2008) 1.33
Detection of genomic amplification of the human telomerase gene (TERC) in cytologic specimens as a genetic test for the diagnosis of cervical dysplasia. Am J Pathol (2003) 1.33
Different types of microsatellite instability in ovarian carcinoma. Int J Cancer (2004) 1.30
Calretinin expression in human normal and neoplastic tissues: a tissue microarray analysis on 5233 tissue samples. Hum Pathol (2003) 1.29
Loss of PBRM1 expression is associated with renal cell carcinoma progression. Int J Cancer (2012) 1.27
Cyclin E overexpression and amplification in human tumours. J Pathol (2003) 1.27
Tissue microarray analysis reveals prognostic significance of syndecan-1 expression in prostate cancer. Prostate (2003) 1.26
URI is an oncogene amplified in ovarian cancer cells and is required for their survival. Cancer Cell (2011) 1.25
Survival benefit for patients with advanced-stage transitional cell carcinomas vs. other subtypes of ovarian carcinoma after chemotherapy with platinum and paclitaxel. Gynecol Oncol (2005) 1.25
Etiology of solitary extrapulmonary positron emission tomography and computed tomography findings in patients with lung cancer. J Clin Oncol (2005) 1.25
Factors to keep in mind when introducing virtual microscopy. Virchows Arch (2005) 1.24
Polyomavirus nephropathy in native kidneys and renal allografts: an update on an escalating threat. Transpl Int (2006) 1.24
Sporadic clear cell renal cell carcinoma but not the papillary type is characterized by severely reduced frequency of primary cilia. Mod Pathol (2008) 1.23
CD133 positive embryonal rhabdomyosarcoma stem-like cell population is enriched in rhabdospheres. PLoS One (2011) 1.22
Periostin is up-regulated in high grade and high stage prostate cancer. BMC Cancer (2010) 1.21
Carcinoma of the collecting ducts of Bellini and renal medullary carcinoma: clinicopathologic analysis of 52 cases of rare aggressive subtypes of renal cell carcinoma with a focus on their interrelationship. Am J Surg Pathol (2012) 1.21
Polyomavirus nephropathy: morphology, pathophysiology, and clinical management. Curr Opin Nephrol Hypertens (2003) 1.20
Expression patterns of potential therapeutic targets in prostate cancer. Int J Cancer (2005) 1.20
VHL-gene deletion in single renal tubular epithelial cells and renal tubular cysts: further evidence for a cyst-dependent progression pathway of clear cell renal carcinoma in von Hippel-Lindau disease. Am J Surg Pathol (2010) 1.19
Expression of epithelial cell adhesion molecule (EpCam) in renal epithelial tumors. Am J Surg Pathol (2005) 1.18
Renal tumors: diagnostic and prognostic biomarkers. Am J Surg Pathol (2013) 1.17
Multi-target fluorescence in situ hybridization in bladder washings for prediction of recurrent bladder cancer. Int J Cancer (2006) 1.15
HER2 analysis in breast cancer: reduced immunoreactivity in FISH non-informative cancer biopsies. Int J Oncol (2004) 1.15
Axillary recurrence rate in breast cancer patients with negative sentinel lymph node (SLN) or SLN micrometastases: prospective analysis of 150 patients after SLN biopsy. Ann Surg (2005) 1.14
Amplification pattern of 12q13-q15 genes (MDM2, CDK4, GLI) in urinary bladder cancer. Oncogene (2002) 1.14
Bace2 is a β cell-enriched protease that regulates pancreatic β cell function and mass. Cell Metab (2011) 1.14
Tumor lymphangiogenesis and metastasis to lymph nodes induced by cancer cell expression of podoplanin. Am J Pathol (2010) 1.13